The short version of regulatory status fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-04 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
=== Video games === Major Force appears as a boss in DC Universe Online, voiced by Alexander Brandon. This version works for Amanda Waller. Major Force appears as a character summon in Scribblenauts Unmasked: A DC Comics Adventure.
== Components == Honey bee venom is a complex mixture of proteins and smaller molecules. The main component is melittin, which amounts to 52% of venom peptides. One of the main allergens is phospholipase A2, which amounts to 12% and is an enzyme that catalyzes the hydrolysis of phospholipids, causing degradation of cell membranes, causing cell death. Adolapin contributes 2–5% of the peptides. Further protein components include apamin (2%), a neurotoxin, hyaluronidase (2%), which dilates blood vessels, increasing their permeability and facilitating the spread of the venom, mast cell degranulating peptide (2%), tertiapin, and secapin. Small molecules in bee venom include histamine (0.1–1%), dopamine and noradrenaline.
By the subsequent Potsdam Agreement, the four Allied Powers asserted joint sovereignty over "Germany as a whole", defined as the totality of the territory within the occupation zones. Former German areas east of the rivers Oder and Neisse and outside of 'Germany as a whole' were officially separated from German sovereignty in August 1945 and transferred from Soviet military occupation to Polish and Soviet (in the case of the territory of Kaliningrad) civil administration, their Polish and Soviet status to be confirmed at a final Peace Treaty. Following wartime commitments by the Allies to the governments-in-exile of Czechoslovakia and Poland, the Potsdam Protocols also agreed to the 'orderly and humane' transfer to Germany as a whole of the ethnic German populations in Poland, Czechoslovakia and Hungary. Eight million German expellees and refugees eventually settled in West Germany. Between 1946 and 1949, three of the occupation zones began to merge. First, the British and American zones were combined into the quasi-state of Bizonia. Soon afterwards, the French zone was included into Trizonia. Conversely, the Soviet zone became East Germany. At the same time, new federal states (Länder) were formed in the Allied zones; replacing the geography of pre-Nazi German states such as the Free State of Prussia and the Republic of Baden, which had derived ultimately from former independent German kingdoms and principalities.
Sources: en.wikipedia.org
=== mRNA Degradation === Degradation of mRNA also plays an important part in regulating the translation process. To explore mechanisms of decay, genome-wide mapping of uncapped and cleaved transcripts (GMUCT), parallel analysis of RNA ends (PARE), and degradome sequencing use the T4 ligase of the Illumina sequencing platform to sequence decapped mRNAs. T4 ligase ligates to RNA with a free 5' monophosphate. As mature mRNAs have a 5' cap, they are not bound as substrates, leaving decapped and degrading mRNAs to be bound. 5′-monophosphorylated ends sequencing (5Pseq) captures both capped and decapped sequences to allow sequencing of both mature mRNA and degraded products. This helps identify mRNA degradation products and has uses in studying ribosome stalling. These methods study 5' to 3' degradation, miRNA-mediated cleavage, and nonsense-mediated mRNA decay, but cannot measure 3' to 5' degradation and other degradation mechanisms.
CYP2D6 inhibitors (e.g., fluoxetine, paroxetine and quinidine) can increase exposure for atomoxetine and it can also increase atomoxetine steady-state plasma concentration. Antihypertensive drugs because it can possibly increase the blood pressure β2-agonist e.g. albuterol because it may increase the efficacy of albuterol on the cardiovascular system. Medicines that affect norepinephrine (e.g. venlafaxine, imipramine, mirtazapine) should be used with caution when administered with atomoxetine due to possible synergy or synergistic effects on pharmacodynamic effects. Beware of taking reboxetine in combination with:
=== Regulations === Because of the adverse effects of cadmium on the environment and human health, the supply and use of cadmium is restricted in Europe under the REACH Regulation. The EFSA Panel on Contaminants in the Food Chain specifies that 2.5 μg/kg body weight is a tolerable weekly intake for humans. The Joint FAO/WHO Expert Committee on Food Additives has declared 7 μg/kg body weight to be the provisional tolerable weekly intake level. The state of California requires a food label to carry a warning about potential exposure to cadmium on products such as cocoa powder. The European Commission has put in place the EU regulation (2019/1009) on fertilizing products (EU, 2019), adopted in June 2019 and fully applicable as of July 2022. It sets a Cd limit value in phosphate fertilizers to 60 mg kg−1 of P2O5. The U.S. Occupational Safety and Health Administration (OSHA) has set the permissible exposure limit (PEL) for cadmium at a time-weighted average (TWA) of 0.005 ppm. The National Institute for Occupational Safety and Health (NIOSH) has not set a recommended exposure limit (REL) and has designated cadmium as a known human carcinogen. The IDLH (immediately dangerous to life and health) level for cadmium is 9 mg/m3.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.